Skip to main content

Table 1 Global monitoring framework targets and indicators

From: Health information priorities for more effective implementation and monitoring of non-communicable disease programs in low- and middle-income countries: lessons from the Pacific

Target

Indicator

1. (a) Reduce premature mortality from NCDs by 25 %

1. Unconditional probability of dying between ages 30 and 70 years from cardiovascular disease (CVD), cancer, diabetes, or chronic respiratory diseases

(b) Cancer morbidity

2. Cancer incidence by type of cancer per 100,000 population

2. At least 10 % relative reduction in the harmful use of alcohol, as appropriate within the national context

3. Total (recorded and unrecorded) alcohol per capita (15+ years old) consumption within a calendar year in litres of pure alcohol, as appropriate within the national context

4. Age-standardised prevalence of heavy episodic drinking among (adolescents and adults) as appropriate within the national context

5. Alcohol-related morbidity and mortality among adolescents and adults, as appropriate within the national context

3. 10 % relative reduction in prevalence of insufficient physical activity

6. Age-standardised prevalence of insufficiently active adults aged 18+ years (defined as less than 150 minutes of moderate intensity activity per week or equivalent)

7. Prevalence of insufficiently physically active adolescents defined as less than 60 minutes of moderate to vigorous intensity activity daily

4. 30 % reduction in mean population intake of salt/sodium

8. Age-standardised mean population intake of salt (sodium chloride) per day in grams in adults aged 18+ years

5. 30 % reduction in prevalence of current tobacco smoking

9. Age-standardised prevalence of current tobacco smoking among persons aged 18+ years

10. Prevalence of current tobacco use among adolescents

6. Halt the rise in diabetes and obesity

11. Age-standardised prevalence of raised blood glucose/diabetes among adults aged 18+ years (defined as fasting plasma glucose value ≥7.0 mmol/L (126 mg/dL) or on medication for raised blood glucose)

12. Age-standardised prevalence of overweight and obesity in adults aged 18+ years (defined as body mass index (BMI) ≥25 kg/m for overweight or ≥30 kg/m for obesity)

13. Prevalence of overweight and obesity in adolescents (defined according to the WHO Growth Reference: overweight – one standard deviation BMI for age and sex, and obese – two standard deviations BMI for age and sex)

7. (a) 25 % relative reduction in the prevalence of raised blood pressure or contain the prevalence of raised blood pressure according to national circumstances

14. Age-standardised prevalence of raised blood pressure among adults aged 18+ years (defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg) and mean systolic blood pressure

(b) Cholesterol

15. Age-standardised prevalence of raised total cholesterol among adults aged 18+ years (defined as total cholesterol ≥5.0 mmol/L or 190 mg/dL

(c) Fat intake

16. Age-standardised mean proportion of total energy intake from saturated fatty acids and polyunsaturated fatty acids in adults aged 18+ years

(d) Fruit and vegetable intake

17. Age-standardised prevalence of adult (aged 18+ years) population consuming less than five total servings (400 g) of fruit and vegetables per day

8. At least 50 % of eligible people receive drug therapy and counselling (including glycaemic control) to prevent heart attacks and strokes

18. Proportion of eligible persons (defined as aged 40 years and over with a 10-year cardiovascular risk greater than or equal to 30 % including those with existing CVD) receiving drug therapy and counselling to prevent heart attacks and strokes

9. (a) An 80 % availability of the affordable basic technologies and essential medicines, including generics, required to treat major non-communicable diseases in both public and private facilities

19. Availability and affordability of quality, safe, and efficacious essential non-communicable disease medicines, including generics, and basic technologies in both public and private facilities

(b) Palliative care

20. Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics (excluding methadone) per death from cancer

(c) Cervical cancer

21. Proportion of women between the ages of 30 and 49 screened for cervical cancer at least once, or more often, and for lower and higher age groups according to programs and policies

(d) Trans-fat elimination

22. Adoption of national policies that virtually eliminate partially hydrogenated vegetable oils in the food supply and replace with polyunsaturated fatty acids

(e) Marketing foods to children

23. Policies to reduce the impact on children of marketing of foods high in saturated fats, trans-fatty acids, free sugars, or salt

(f) Vaccination against cancer-causing infections

24. Vaccination coverage against hepatitis B virus monitored by number of third doses of Hep-B vaccine (HepB3) administered to infants

25. Availability, as appropriate, if cost-effective and affordable, of vaccines against human papillomavirus, according to national programmes and policies